0.29
+6.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Evogene
Its shares trade under the ticker EVGN. It has been listed since 11 June 2007. In the fiscal year to 31 December 2025, it reported revenue of $3.9m and a net loss of $8.5m. At that date it held total assets of $20.0m and shareholders' equity of −$82,000.
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. The firm is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The firm operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). The company operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The firm's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The firm's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jun 2007
- Employees
- 150
- Website
- evogene.com ↗
- Head office
- 13 GAD FEINSTEIN STREET, REHOVOT, L3, 7638517
- Incorporated in
- L3
- Classification
- Agricultural Chemicals
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Mr. Nir NimrodiChairman of the Board, since 2025
- Mr. Ofer HavivPresident, Chief Executive Officer, since 2002$530,000
- Ms. Dorit KreinerChief Financial Officer$276,000
- Dr. Brian EmberChief Executive Officer of AgPlenus Limited
- Dr. Elran HaberChief Executive Officer of Biomica Limited$484,000
- Dr. Arnon HeymanChief Executive Officer of Canonic Limited$275,000
- Mr. Mark KapelExecutive Vice President - Technology$309,000
- Mr. Sassi MasliahExecutive Vice President - Corporate Development
- Dr. Nir ArbelChief Product Officer
- Mr. Dan FalkIndependent Director
- Ms. Sarit FironIndependent Director
- Mr. Ziv KopIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Evogene Ltd has several strengths that contribute to its competitive advantage:
Weaknesses
- Evogene Ltd also faces certain weaknesses that can hinder its progress:
Opportunities
- Evogene Ltd can leverage the following opportunities for future growth:
Threats
- Evogene Ltd must navigate the following threats that could impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.